Welcome to our dedicated page for Volitionrx SEC filings (Ticker: VNRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The VolitionRx Limited (VNRX) SEC filings page provides direct access to the company’s U.S. regulatory disclosures, including current reports on Form 8-K, periodic reports, and registration-related documents. As a NYSE American-listed issuer, VolitionRx uses these filings to report material agreements, capital-raising transactions, governance changes, and other significant events related to its epigenetics and diagnostic testing business.
Recent Forms 8-K describe several key financing arrangements, such as an amended and restated securities purchase agreement with an institutional investor involving a senior secured convertible promissory note and common stock purchase warrant, underwritten public offerings of common stock and warrants, and a registered direct offering of shares and warrants to existing stockholders and insiders. Other 8-K filings detail amendments to the company’s certificate of incorporation to increase authorized common stock, results of stockholder votes at the annual meeting, and announcements of quarterly financial results and business updates.
These filings also outline the terms of VolitionRx’s securities, including conversion prices, warrant exercise prices, ownership limitations, repayment schedules, security interests in company assets, and conditions that constitute events of default. Investors can review how the company structures its capital, secures funding for research and commercialization of its Nu.Q® and related platforms, and manages its obligations to lenders and underwriters.
On Stock Titan, each VolitionRx filing is accompanied by AI-powered summaries that highlight the most important points, such as new financing terms, changes to authorized share capital, or disclosure of financial results. Users can quickly see which filings relate to earnings (often furnished under Item 2.02), which involve material definitive agreements (Item 1.01), and which concern governance or charter amendments (Items 5.02 and 5.03). This structure helps readers navigate lengthy documents and focus on the aspects most relevant to their analysis of VNRX.
VolitionRx Ltd director Ethel Rubin reported an equity award tied to performance goals. On March 17, 2025 she was granted 40,000 restricted stock units (RSUs) under the company’s 2024 Stock Incentive Plan. Certain corporate performance goals were achieved, so rights to 12,000 RSUs vested and were reflected as an acquisition of 12,000 shares of common stock at $0 on January 22, 2026, bringing her directly held common stock to 74,948 shares.
The 12,000 vested RSUs are subject to a three-year time-based schedule, vesting in three equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each vested RSU. The rights to the remaining 28,000 RSUs from the original grant did not vest based on the applicable performance goals and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd director Guy Archibald Innes filed a Form 4 reporting equity compensation tied to prior restricted stock unit (RSU) awards. On March 17, 2025 he was granted 40,000 RSUs under the 2024 Stock Incentive Plan, subject to corporate performance and time-based vesting conditions. Certain performance goals were achieved, so rights with respect to 12,000 RSUs vested, while the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026.
Following the reported transaction, Innes directly holds 1,074,967 shares of common stock. He also has indirect interests, including 1,400,000 shares held by The Innes Family Bare Trust 2023 and 356,000 shares held by The Dill Faulkes Educational Trust Limited, where he disclaims beneficial ownership except to the extent of any pecuniary interest.
VolitionRx Ltd Chief Commercial Officer Gael Forterre reported an acquisition of 38,100 shares of common stock on January 22, 2026, at a price of $0 per share, reflecting vesting of previously granted restricted stock units (RSUs). Following this transaction, he directly holds 191,882 shares of common stock, with additional indirect holdings of 5,000 shares held by his spouse and 32,500 shares held by Armorica Partners, LLC, an entity he controls.
The footnotes explain that he was granted 127,000 RSUs on March 17, 2025 under the 2024 Stock Incentive Plan. Corporate performance goals were partially met, causing 38,100 RSUs to vest, while the remaining 88,900 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested RSUs remain subject to a three-year time-based schedule, vesting in three equal installments of 12,700 units on each of March 17, 2026, 2027 and 2028, when settled into common stock.
VolitionRx Ltd. President and CEO Cameron John Reynolds reported an award of 74,700 shares of common stock at $0.00 per share, following the vesting of restricted stock units (RSUs) tied to performance goals. These RSUs come from a March 17, 2025 grant of 249,000 RSUs under the company’s 2024 Stock Incentive Plan, where only a portion vested after certain corporate performance goals were achieved. The vested RSUs are subject to a three-year time-based schedule, with 24,900 units scheduled to vest on each of March 17, 2026, 2027 and 2028, delivering an equal number of common shares upon settlement. After this transaction, Reynolds directly holds 2,629,547 VolitionRx common shares, with additional indirect holdings of 1,007,718 shares through Concord International, Inc. and 34,076 shares held by his spouse.
VolitionRx Ltd director Alan Colman reported receiving 12,000 shares of common stock on January 22, 2026, coded as an acquisition at a price of $0 per share. Following this transaction, he beneficially owned 257,364 shares of VolitionRx common stock in direct ownership.
The filing explains that on March 17, 2025, he had been granted 40,000 restricted stock units (RSUs) under the 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Performance conditions were satisfied for 12,000 RSUs, while the remaining 28,000 RSUs did not vest and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd. director Timothy I. Still reported the acquisition of 90,000 shares of common stock on January 22, 2026, shown at a price of
The footnote explains that on March 17, 2025, Still received 300,000 RSUs tied to corporate performance goals and time-based vesting. Only the performance goals for 90,000 RSUs were met; the remaining 210,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The 90,000 RSUs that satisfied performance conditions are scheduled to vest in three equal installments of 30,000 units on March 17, 2026, 2027 and 2028, after which an equivalent number of common shares will be delivered.
VolitionRx Ltd's Group Chief Marketing Officer, Ann-Louise Batchelor, reported the acquisition of 33,900 shares of common stock on January 22, 2026 at a price of $0 per share, reflecting vesting of restricted stock units (RSUs) granted under the company’s 2024 Stock Incentive Plan. She now beneficially owns 182,072 common shares directly and 29,406 shares indirectly through her spouse.
The RSUs were part of a 113,000-unit award granted on March 17, 2025, tied to corporate performance goals and time-based vesting. Performance goals were met for 33,900 RSUs, while the remaining 79,100 RSUs were cancelled after targets were not achieved by June 30, 2025 and January 22, 2026.
VolitionRx Ltd.'s Chief Financial Officer, Terig Hughes, reported an acquisition of 49,200 shares of common stock on January 22, 2026, at a price of $0 per share. This reflects the vesting of part of a prior award of 164,000 restricted stock units (RSUs) granted on March 17, 2025 under the company’s 2024 Stock Incentive Plan.
Certain corporate performance goals were achieved, causing rights with respect to 49,200 RSUs to vest. These RSUs are subject to a three-year time-based vesting schedule in equal installments of 16,400 units on each of March 17, 2026, 2027 and 2028, after which shares are delivered upon settlement. Rights relating to the remaining 114,800 RSUs from the original grant did not vest and were cancelled on June 30, 2025 and January 22, 2026.
VolitionRx Ltd director Phillip Barnes reported acquiring 12,000 shares of common stock on January 22, 2026 at a price of $0, increasing his direct holdings to 67,368 shares. These shares relate to a grant of 40,000 restricted stock units (RSUs) awarded on March 17, 2025 under the company’s 2024 Stock Incentive Plan.
The RSUs were tied to corporate performance goals and time-based vesting. Only the targets for 12,000 RSUs were achieved; the remaining 28,000 RSUs were cancelled on June 30, 2025 and January 22, 2026. The vested portion is scheduled to vest over three years in equal installments of 4,000 units on March 17, 2026, 2027 and 2028, with one share of common stock delivered for each RSU that ultimately vests.
VolitionRx Ltd CEO Salvatore Thomas Butera reported an equity award related to restricted stock units (RSUs). On March 17, 2025 he was granted 178,000 RSUs under the company’s 2024 Stock Incentive Plan, tied to corporate performance goals and time-based vesting. Certain performance goals were achieved, causing 53,400 RSUs to vest, which are reported as an acquisition of 53,400 shares of common stock at a price of
The 53,400 vested RSUs are subject to a 3‑year time-based schedule, vesting in three equal installments of 17,800 units on each of
FAQ
What is the current stock price of Volitionrx (VNRX)?
What is the market cap of Volitionrx (VNRX)?
